A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy.

Trial Profile

A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Carboplatin
  • Indications Ovarian cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 02 Aug 2009 Actual end date (Apr 2002) added as reported by National Cancer Institute of Canada.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top